Multiple sclerosis therapy with transdermal myelin peptide stimulation
Multiple sclerosis therapy with transdermal myelin peptide stimulation.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- PLP peptide
Compared with
- Interferon beta-1a
Interferon alpha/beta receptor agonist
What it measured
Main measures
The demonstration that myelin MBP85-99, MOG 35-55 PLP139-151 peptide mixture reduces the amount of relapses as compared to treatment with interferon beta 1A.
RelapsesImmune response
Other measures (1)
- cumulative number of gadolinium positive changes in MRI
MRI lesions
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: The signing of informed consent to participate in the study Exclusion: Patients with diagnosis of SP MS and PP MS.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The demonstration that myelin MBP85-99, MOG 35-55 PLP139-151 peptide mixture reduces the amount of relapses as compared to treatment with interferon beta 1A.
Loading reviews and guidelines…
History
Started
Jul 2016